JP2011500854A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011500854A5 JP2011500854A5 JP2010531321A JP2010531321A JP2011500854A5 JP 2011500854 A5 JP2011500854 A5 JP 2011500854A5 JP 2010531321 A JP2010531321 A JP 2010531321A JP 2010531321 A JP2010531321 A JP 2010531321A JP 2011500854 A5 JP2011500854 A5 JP 2011500854A5
- Authority
- JP
- Japan
- Prior art keywords
- fluid
- ppm
- lung
- respiratory disorder
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 54
- 239000012530 fluid Substances 0.000 claims description 51
- 210000004072 lung Anatomy 0.000 claims description 33
- 208000023504 respiratory system disease Diseases 0.000 claims description 29
- 208000019693 Lung disease Diseases 0.000 claims description 28
- 239000003814 drug Substances 0.000 claims description 21
- 229940124597 therapeutic agent Drugs 0.000 claims description 20
- 208000006673 asthma Diseases 0.000 claims description 16
- 210000004027 cell Anatomy 0.000 claims description 16
- 208000024891 symptom Diseases 0.000 claims description 15
- 230000000694 effects Effects 0.000 claims description 13
- 230000004068 intracellular signaling Effects 0.000 claims description 13
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 12
- 239000001301 oxygen Substances 0.000 claims description 12
- 229910052760 oxygen Inorganic materials 0.000 claims description 12
- 210000002390 cell membrane structure Anatomy 0.000 claims description 11
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 10
- 102100038497 Cytokine receptor-like factor 2 Human genes 0.000 claims description 10
- 210000004379 membrane Anatomy 0.000 claims description 10
- 239000012528 membrane Substances 0.000 claims description 10
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 8
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims description 8
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims description 8
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical group CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims description 8
- 229960004436 budesonide Drugs 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 229960002052 salbutamol Drugs 0.000 claims description 8
- 101710194733 Cytokine receptor-like factor 2 Proteins 0.000 claims description 6
- 102000034353 G alpha subunit Human genes 0.000 claims description 6
- 108091006099 G alpha subunit Proteins 0.000 claims description 6
- 239000000556 agonist Substances 0.000 claims description 6
- 239000005557 antagonist Substances 0.000 claims description 6
- 239000003246 corticosteroid Substances 0.000 claims description 6
- 229960002714 fluticasone Drugs 0.000 claims description 6
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims description 6
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 claims description 4
- PFWLFWPASULGAN-UHFFFAOYSA-N 7-methylxanthine Chemical compound N1C(=O)NC(=O)C2=C1N=CN2C PFWLFWPASULGAN-UHFFFAOYSA-N 0.000 claims description 4
- 206010014561 Emphysema Diseases 0.000 claims description 4
- 101000956427 Homo sapiens Cytokine receptor-like factor 2 Proteins 0.000 claims description 4
- 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 claims description 4
- 208000032376 Lung infection Diseases 0.000 claims description 4
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims description 4
- 201000005702 Pertussis Diseases 0.000 claims description 4
- 206010035664 Pneumonia Diseases 0.000 claims description 4
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 4
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims description 4
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 claims description 4
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 claims description 4
- 102000030621 adenylate cyclase Human genes 0.000 claims description 4
- 108060000200 adenylate cyclase Proteins 0.000 claims description 4
- 230000000172 allergic effect Effects 0.000 claims description 4
- 201000010105 allergic rhinitis Diseases 0.000 claims description 4
- 208000010668 atopic eczema Diseases 0.000 claims description 4
- 230000027455 binding Effects 0.000 claims description 4
- 206010006451 bronchitis Diseases 0.000 claims description 4
- 239000000812 cholinergic antagonist Substances 0.000 claims description 4
- 230000008602 contraction Effects 0.000 claims description 4
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 claims description 4
- 210000000981 epithelium Anatomy 0.000 claims description 4
- 229960002848 formoterol Drugs 0.000 claims description 4
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims description 4
- 239000003862 glucocorticoid Substances 0.000 claims description 4
- 210000003630 histaminocyte Anatomy 0.000 claims description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 4
- 206010022000 influenza Diseases 0.000 claims description 4
- 230000003834 intracellular effect Effects 0.000 claims description 4
- 229960001888 ipratropium Drugs 0.000 claims description 4
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 claims description 4
- 150000002617 leukotrienes Chemical class 0.000 claims description 4
- 239000003607 modifier Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 206010039083 rhinitis Diseases 0.000 claims description 4
- 229960004017 salmeterol Drugs 0.000 claims description 4
- 239000003381 stabilizer Substances 0.000 claims description 4
- 230000009885 systemic effect Effects 0.000 claims description 4
- 229940037128 systemic glucocorticoids Drugs 0.000 claims description 4
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims description 4
- 102000027257 transmembrane receptors Human genes 0.000 claims description 4
- 108091008578 transmembrane receptors Proteins 0.000 claims description 4
- 201000008827 tuberculosis Diseases 0.000 claims description 4
- 230000001413 cellular effect Effects 0.000 claims description 3
- -1 vitorterol Chemical compound 0.000 claims description 3
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 claims description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims description 2
- 229930182837 (R)-adrenaline Natural products 0.000 claims description 2
- NDAUXUAQIAJITI-LBPRGKRZSA-N (R)-salbutamol Chemical compound CC(C)(C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-LBPRGKRZSA-N 0.000 claims description 2
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 claims description 2
- 206010003557 Asthma exercise induced Diseases 0.000 claims description 2
- 206010006482 Bronchospasm Diseases 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 claims description 2
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 claims description 2
- 206010011224 Cough Diseases 0.000 claims description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 2
- 108010036949 Cyclosporine Proteins 0.000 claims description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 2
- 208000004657 Exercise-Induced Asthma Diseases 0.000 claims description 2
- 108060003951 Immunoglobulin Proteins 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 108090000862 Ion Channels Proteins 0.000 claims description 2
- 102000004310 Ion Channels Human genes 0.000 claims description 2
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 claims description 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 2
- 102000014384 Type C Phospholipases Human genes 0.000 claims description 2
- 108010079194 Type C Phospholipases Proteins 0.000 claims description 2
- YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 claims description 2
- 229940125715 antihistaminic agent Drugs 0.000 claims description 2
- 239000000739 antihistaminic agent Substances 0.000 claims description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims description 2
- 229960002170 azathioprine Drugs 0.000 claims description 2
- 229940092705 beclomethasone Drugs 0.000 claims description 2
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims description 2
- 230000033228 biological regulation Effects 0.000 claims description 2
- 230000007885 bronchoconstriction Effects 0.000 claims description 2
- 229940124630 bronchodilator Drugs 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 230000003197 catalytic effect Effects 0.000 claims description 2
- 230000021164 cell adhesion Effects 0.000 claims description 2
- 229960001803 cetirizine Drugs 0.000 claims description 2
- 229960003728 ciclesonide Drugs 0.000 claims description 2
- 229960001265 ciclosporin Drugs 0.000 claims description 2
- 238000002648 combination therapy Methods 0.000 claims description 2
- 229960000265 cromoglicic acid Drugs 0.000 claims description 2
- 229940109248 cromoglycate Drugs 0.000 claims description 2
- 229930182912 cyclosporin Natural products 0.000 claims description 2
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 claims description 2
- 230000001419 dependent effect Effects 0.000 claims description 2
- 210000001047 desmosome Anatomy 0.000 claims description 2
- 229910001882 dioxygen Inorganic materials 0.000 claims description 2
- 229960000520 diphenhydramine Drugs 0.000 claims description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims description 2
- 229960002179 ephedrine Drugs 0.000 claims description 2
- 229960005139 epinephrine Drugs 0.000 claims description 2
- 208000024695 exercise-induced bronchoconstriction Diseases 0.000 claims description 2
- 229960000676 flunisolide Drugs 0.000 claims description 2
- 108020001507 fusion proteins Proteins 0.000 claims description 2
- 102000037865 fusion proteins Human genes 0.000 claims description 2
- 210000003976 gap junction Anatomy 0.000 claims description 2
- 229960000890 hydrocortisone Drugs 0.000 claims description 2
- 229960000930 hydroxyzine Drugs 0.000 claims description 2
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 claims description 2
- 210000000987 immune system Anatomy 0.000 claims description 2
- 102000018358 immunoglobulin Human genes 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 102000006495 integrins Human genes 0.000 claims description 2
- 108010044426 integrins Proteins 0.000 claims description 2
- 210000004347 intestinal mucosa Anatomy 0.000 claims description 2
- 230000031146 intracellular signal transduction Effects 0.000 claims description 2
- 229960001361 ipratropium bromide Drugs 0.000 claims description 2
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 claims description 2
- 229950008204 levosalbutamol Drugs 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 229960003088 loratadine Drugs 0.000 claims description 2
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 claims description 2
- 229960004584 methylprednisolone Drugs 0.000 claims description 2
- 230000004048 modification Effects 0.000 claims description 2
- 238000012986 modification Methods 0.000 claims description 2
- 229960001664 mometasone Drugs 0.000 claims description 2
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 claims description 2
- 229960005127 montelukast Drugs 0.000 claims description 2
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 claims description 2
- 229960004866 mycophenolate mofetil Drugs 0.000 claims description 2
- RQTOOFIXOKYGAN-UHFFFAOYSA-N nedocromil Chemical compound CCN1C(C(O)=O)=CC(=O)C2=C1C(CCC)=C1OC(C(O)=O)=CC(=O)C1=C2 RQTOOFIXOKYGAN-UHFFFAOYSA-N 0.000 claims description 2
- 229960004398 nedocromil Drugs 0.000 claims description 2
- 230000003472 neutralizing effect Effects 0.000 claims description 2
- 229960000470 omalizumab Drugs 0.000 claims description 2
- 150000002926 oxygen Chemical class 0.000 claims description 2
- 230000007170 pathology Effects 0.000 claims description 2
- 230000037361 pathway Effects 0.000 claims description 2
- KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 claims description 2
- 229960005330 pimecrolimus Drugs 0.000 claims description 2
- 229960004583 pranlukast Drugs 0.000 claims description 2
- UAJUXJSXCLUTNU-UHFFFAOYSA-N pranlukast Chemical compound C=1C=C(OCCCCC=2C=CC=CC=2)C=CC=1C(=O)NC(C=1)=CC=C(C(C=2)=O)C=1OC=2C=1N=NNN=1 UAJUXJSXCLUTNU-UHFFFAOYSA-N 0.000 claims description 2
- 229960005205 prednisolone Drugs 0.000 claims description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 2
- 229960004618 prednisone Drugs 0.000 claims description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 2
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 claims description 2
- 102000005962 receptors Human genes 0.000 claims description 2
- 108020003175 receptors Proteins 0.000 claims description 2
- 229960001967 tacrolimus Drugs 0.000 claims description 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims description 2
- 229960000195 terbutaline Drugs 0.000 claims description 2
- 229960000278 theophylline Drugs 0.000 claims description 2
- 210000001578 tight junction Anatomy 0.000 claims description 2
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 claims description 2
- 229940110309 tiotropium Drugs 0.000 claims description 2
- 229960005294 triamcinolone Drugs 0.000 claims description 2
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 229960004764 zafirlukast Drugs 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims 3
- 239000007789 gas Substances 0.000 claims 2
- 239000002086 nanomaterial Substances 0.000 claims 2
- 239000000853 adhesive Substances 0.000 claims 1
- 230000001070 adhesive effect Effects 0.000 claims 1
- 230000004075 alteration Effects 0.000 claims 1
- 229960003556 aminophylline Drugs 0.000 claims 1
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 claims 1
- 230000001387 anti-histamine Effects 0.000 claims 1
- 230000009134 cell regulation Effects 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 210000004692 intercellular junction Anatomy 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- MWLSOWXNZPKENC-SSDOTTSWSA-N zileuton Chemical compound C1=CC=C2SC([C@H](N(O)C(N)=O)C)=CC2=C1 MWLSOWXNZPKENC-SSDOTTSWSA-N 0.000 claims 1
- 229960005332 zileuton Drugs 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 102000010970 Connexin Human genes 0.000 description 1
- 108050001175 Connexin Proteins 0.000 description 1
- 102000000591 Tight Junction Proteins Human genes 0.000 description 1
- 108010002321 Tight Junction Proteins Proteins 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229960000797 oxitropium Drugs 0.000 description 1
- NVOYVOBDTVTBDX-PMEUIYRNSA-N oxitropium Chemical compound CC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1 NVOYVOBDTVTBDX-PMEUIYRNSA-N 0.000 description 1
- 208000017443 reproductive system disease Diseases 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
Applications Claiming Priority (21)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98272007P | 2007-10-25 | 2007-10-25 | |
| US98271907P | 2007-10-25 | 2007-10-25 | |
| PCT/US2007/082580 WO2008052145A2 (en) | 2006-10-25 | 2007-10-25 | Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution |
| PCT/US2007/082581 WO2008115290A2 (en) | 2006-10-25 | 2007-10-25 | Methods of wound care and treatment |
| USPCT/US2007/082581 | 2007-10-25 | ||
| USPCT/US2007/082578 | 2007-10-25 | ||
| USPCT/US2007/082580 | 2007-10-25 | ||
| PCT/US2007/082578 WO2008052143A2 (en) | 2006-10-25 | 2007-10-25 | Mixing device and output fluids of same |
| US60/982,720 | 2007-10-25 | ||
| US60/982,719 | 2007-10-25 | ||
| US4833208P | 2008-04-28 | 2008-04-28 | |
| US4840408P | 2008-04-28 | 2008-04-28 | |
| US4834008P | 2008-04-28 | 2008-04-28 | |
| US4834708P | 2008-04-28 | 2008-04-28 | |
| US4841608P | 2008-04-28 | 2008-04-28 | |
| US61/048,404 | 2008-04-28 | ||
| US61/048,416 | 2008-04-28 | ||
| US61/048,347 | 2008-04-28 | ||
| US61/048,340 | 2008-04-28 | ||
| US61/048,332 | 2008-04-28 | ||
| PCT/US2008/081386 WO2009055824A1 (en) | 2007-10-25 | 2008-10-27 | Compositions and methods for treating asthma and lung disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014228037A Division JP5750540B2 (ja) | 2007-10-25 | 2014-11-10 | 喘息および他の肺障害を治療するための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011500854A JP2011500854A (ja) | 2011-01-06 |
| JP2011500854A5 true JP2011500854A5 (https=) | 2011-12-15 |
| JP5647897B2 JP5647897B2 (ja) | 2015-01-07 |
Family
ID=42238385
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010531258A Expired - Fee Related JP5586470B2 (ja) | 2007-10-25 | 2008-10-23 | 静菌性または殺菌性組成物および方法 |
| JP2010531321A Expired - Fee Related JP5647897B2 (ja) | 2007-10-25 | 2008-10-27 | 喘息および他の肺障害を治療するための組成物および方法 |
| JP2014228037A Expired - Fee Related JP5750540B2 (ja) | 2007-10-25 | 2014-11-10 | 喘息および他の肺障害を治療するための組成物および方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010531258A Expired - Fee Related JP5586470B2 (ja) | 2007-10-25 | 2008-10-23 | 静菌性または殺菌性組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014228037A Expired - Fee Related JP5750540B2 (ja) | 2007-10-25 | 2014-11-10 | 喘息および他の肺障害を治療するための組成物および方法 |
Country Status (8)
| Country | Link |
|---|---|
| EP (2) | EP2207669A4 (https=) |
| JP (3) | JP5586470B2 (https=) |
| CN (3) | CN101909869B (https=) |
| AU (2) | AU2008316708A1 (https=) |
| CA (2) | CA2703648A1 (https=) |
| IL (2) | IL205321A0 (https=) |
| MX (1) | MX2010004549A (https=) |
| WO (1) | WO2009055620A1 (https=) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6702949B2 (en) | 1997-10-24 | 2004-03-09 | Microdiffusion, Inc. | Diffuser/emulsifier for aquaculture applications |
| US8445546B2 (en) | 2006-10-25 | 2013-05-21 | Revalesio Corporation | Electrokinetically-altered fluids comprising charge-stabilized gas-containing nanostructures |
| US8597689B2 (en) | 2006-10-25 | 2013-12-03 | Revalesio Corporation | Methods of wound care and treatment |
| AU2007308838B2 (en) | 2006-10-25 | 2014-03-13 | Revalesio Corporation | Mixing device and output fluids of same |
| MX2010004549A (es) * | 2007-10-25 | 2010-07-28 | Revalesio Corp | Composiciones y métodos bacteriostáticos o bactericidas. |
| US10125359B2 (en) | 2007-10-25 | 2018-11-13 | Revalesio Corporation | Compositions and methods for treating inflammation |
| US9523090B2 (en) | 2007-10-25 | 2016-12-20 | Revalesio Corporation | Compositions and methods for treating inflammation |
| EP2215260A4 (en) * | 2007-10-25 | 2011-04-20 | Revalesio Corp | COMPOSITIONS AND METHOD FOR MODULATING CELL MEMBRANE-IMPROVED INTRA-CELLULAR SIGNAL TRANSMISSION |
| US9745567B2 (en) | 2008-04-28 | 2017-08-29 | Revalesio Corporation | Compositions and methods for treating multiple sclerosis |
| US8980325B2 (en) | 2008-05-01 | 2015-03-17 | Revalesio Corporation | Compositions and methods for treating digestive disorders |
| US8399006B2 (en) | 2009-01-29 | 2013-03-19 | Forsight Vision4, Inc. | Posterior segment drug delivery |
| US8623395B2 (en) | 2010-01-29 | 2014-01-07 | Forsight Vision4, Inc. | Implantable therapeutic device |
| US8815292B2 (en) | 2009-04-27 | 2014-08-26 | Revalesio Corporation | Compositions and methods for treating insulin resistance and diabetes mellitus |
| US10166142B2 (en) | 2010-01-29 | 2019-01-01 | Forsight Vision4, Inc. | Small molecule delivery with implantable therapeutic device |
| BR112012028540A2 (pt) | 2010-05-07 | 2016-07-26 | Revalesio Corp | composições e métodos para melhorar desempenho fisiológico e tempo de recuperação |
| EP3861969A1 (en) | 2010-08-05 | 2021-08-11 | ForSight Vision4, Inc. | Injector apparatus for drug delivery |
| JP6111194B2 (ja) | 2010-08-05 | 2017-04-05 | フォーサイト・ビジョン フォー・インコーポレーテッド | 組み合わせ薬物送達方法および装置 |
| SI2600812T1 (sl) | 2010-08-05 | 2021-12-31 | ForSight Vision4, Inc., | Naprava za zdravljenje očesa |
| JP2013533320A (ja) | 2010-08-12 | 2013-08-22 | レバレジオ コーポレイション | タウオパチーを治療するための組成物および方法 |
| WO2012068549A2 (en) | 2010-11-19 | 2012-05-24 | Forsight Vision4, Inc. | Therapeutic agent formulations for implanted devices |
| EP4249059B1 (en) | 2011-06-28 | 2025-07-30 | ForSight Vision4, Inc. | An apparatus for collecting a sample of fluid from a reservoir chamber of a therapeutic device for the eye |
| RS61758B1 (sr) | 2011-09-16 | 2021-05-31 | Forsight Vision4 Inc | Aparati za razmenu tečnosti |
| US10010448B2 (en) | 2012-02-03 | 2018-07-03 | Forsight Vision4, Inc. | Insertion and removal methods and apparatus for therapeutic devices |
| JP6159584B2 (ja) * | 2012-06-14 | 2017-07-05 | 松本 高明 | 輸液、輸液の製造方法および輸液装置 |
| CA2905496A1 (en) | 2013-03-14 | 2014-09-25 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
| ES2972168T3 (es) | 2013-03-28 | 2024-06-11 | Forsight Vision4 Inc | Implante oftálmico para administración de sustancias terapéuticas |
| GB201402513D0 (en) * | 2014-02-13 | 2014-04-02 | Cardiff Scintigraphics Ltd | Pressurised metered dose inhalers and method of manufacture |
| KR101930573B1 (ko) * | 2014-04-23 | 2018-12-18 | 주식회사 티씨엠생명과학 | 세포 도말 장치 및 세포 도말 방법 |
| EP3169289B1 (en) | 2014-07-15 | 2020-04-15 | ForSight Vision4, Inc. | Ocular implant delivery device |
| BR112017002466A2 (pt) | 2014-08-08 | 2017-12-05 | Forsight Vision4 Inc | formulações estáveis e solúveis de inibidores da tirosina cinase do receptor, e métodos para a sua preparação |
| WO2016077371A1 (en) | 2014-11-10 | 2016-05-19 | Forsight Vision4, Inc. | Expandable drug delivery devices and method of use |
| CA3005238A1 (en) | 2015-11-20 | 2017-05-26 | Forsight Vision4, Inc. | Porous structures for extended release drug delivery devices |
| JP7009384B2 (ja) | 2016-04-05 | 2022-01-25 | フォーサイト・ビジョン フォー・インコーポレーテッド | 移植可能な眼薬送達デバイス |
| JP7287888B2 (ja) * | 2016-06-27 | 2023-06-06 | ギャラリー，インコーポレイテッド | ジェネレータ、電極付きのカテーテル、及び肺通路の治療方法 |
| KR20200093581A (ko) | 2017-11-21 | 2020-08-05 | 포사이트 비젼4, 인크. | 확장 가능한 포트 전달 시스템을 위한 유체 교환 기기 및 사용 방법 |
| US11759677B2 (en) | 2018-02-16 | 2023-09-19 | University Of Louisville Research Foundation, Inc. | Respiratory training and airway pressure monitoring device |
| KR102171489B1 (ko) * | 2018-10-30 | 2020-10-29 | (주)메가메디칼 | 네블라이저 및 산소공급기가 구비되는 네블라이저 장치 |
| EP4125847A4 (en) * | 2020-04-03 | 2024-06-19 | Lpoxy Therapeutics, Inc. | ENTERAL AEROBIZATION THERAPY |
| US20230210848A1 (en) * | 2020-04-30 | 2023-07-06 | Fujifilm Toyama Chemical Co., Ltd. | Coronavirus infection therapeutic agent formed through combination of pyrazine derivative and another coronavirus infection therapeutic drug |
| USD1033637S1 (en) | 2022-01-24 | 2024-07-02 | Forsight Vision4, Inc. | Fluid exchange device |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH1157720A (ja) * | 1996-11-07 | 1999-03-02 | Honda Motor Co Ltd | 電解機能水、その製造方法及び製造装置 |
| US7654728B2 (en) * | 1997-10-24 | 2010-02-02 | Revalesio Corporation | System and method for therapeutic application of dissolved oxygen |
| IL124788A (en) * | 1998-06-07 | 1999-04-11 | Ben Hador David | Boomerang launcher |
| US6477410B1 (en) * | 2000-05-31 | 2002-11-05 | Biophoretic Therapeutic Systems, Llc | Electrokinetic delivery of medicaments |
| US20060198901A9 (en) * | 1999-10-26 | 2006-09-07 | Holloway William D Jr | Drugs, bio-affecting and body treating compositions |
| EP1237578A4 (en) * | 1999-10-26 | 2004-10-27 | Bio Hydration Res Lab Inc | MICRO-AGGREGATED LIQUIDS AND METHODS OF MAKING AND USING SAME |
| US6426066B1 (en) * | 2000-01-12 | 2002-07-30 | California Pacific Labs, Inc. | Use of physiologically balanced, ionized, acidic solution in wound healing |
| JP4064671B2 (ja) * | 2000-02-25 | 2008-03-19 | エフ．ホフマン−ラ ロシュ アーゲー | アデノシン受容体モジュレーター |
| EP1357920B1 (en) * | 2001-02-01 | 2007-09-05 | Hydron Technologies Inc. | Compositions and method of tissue superoxygenation |
| US20030199089A1 (en) * | 2001-06-05 | 2003-10-23 | Surber Mark W. | Membrane to membrane delivery |
| US20030232114A1 (en) * | 2002-06-13 | 2003-12-18 | Nikola Dekleva | Method for liquid enrichment with oxygen and applications of enriched liquids |
| AU2002321678A1 (en) * | 2002-09-09 | 2004-03-29 | Boros Béla | Oxygen-enriched water, treated within a magnetic field and heavy water |
| TWI359675B (en) * | 2003-07-10 | 2012-03-11 | Dey L P | Bronchodilating β-agonist compositions |
| ATE500234T1 (de) * | 2003-11-10 | 2011-03-15 | Merck Sharp & Dohme | Substituierte trialzole als blocker des natriumkanals |
| JP4144669B2 (ja) * | 2004-03-05 | 2008-09-03 | 独立行政法人産業技術総合研究所 | ナノバブルの製造方法 |
| US20060073212A1 (en) * | 2004-04-22 | 2006-04-06 | Palmer Craig R | Method of treating respiratory disorders and airway inflammation |
| CA2574848A1 (en) * | 2004-08-05 | 2006-12-21 | Wyeth | Antagonizing interleukin-21 receptor activity |
| US20060273016A1 (en) * | 2005-06-03 | 2006-12-07 | BAGLEY David | Method for preparing water with a stable negative oxidation reduction potential (ORP) |
| WO2008018932A2 (en) * | 2006-05-01 | 2008-02-14 | The Board Of Trustees Of The Leland Stanford Junior University | Method and use of nano-scale devices for reduction of tissue injury in ischemic and reperfusion injury |
| AU2007308838B2 (en) * | 2006-10-25 | 2014-03-13 | Revalesio Corporation | Mixing device and output fluids of same |
| JP5491185B2 (ja) * | 2006-10-25 | 2014-05-14 | リバルシオ コーポレイション | 傷のケアおよび処置の方法 |
| EP2215260A4 (en) * | 2007-10-25 | 2011-04-20 | Revalesio Corp | COMPOSITIONS AND METHOD FOR MODULATING CELL MEMBRANE-IMPROVED INTRA-CELLULAR SIGNAL TRANSMISSION |
| MX2010004549A (es) * | 2007-10-25 | 2010-07-28 | Revalesio Corp | Composiciones y métodos bacteriostáticos o bactericidas. |
| US20090227018A1 (en) * | 2007-10-25 | 2009-09-10 | Revalesio Corporation | Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction |
| JP2011050844A (ja) * | 2009-09-01 | 2011-03-17 | Kurita Water Ind Ltd | 電気浸透脱水方法及び装置 |
-
2008
- 2008-10-23 MX MX2010004549A patent/MX2010004549A/es active IP Right Grant
- 2008-10-23 CA CA2703648A patent/CA2703648A1/en not_active Abandoned
- 2008-10-23 AU AU2008316708A patent/AU2008316708A1/en not_active Abandoned
- 2008-10-23 JP JP2010531258A patent/JP5586470B2/ja not_active Expired - Fee Related
- 2008-10-23 WO PCT/US2008/081029 patent/WO2009055620A1/en not_active Ceased
- 2008-10-23 CN CN200880122810.7A patent/CN101909869B/zh not_active Expired - Fee Related
- 2008-10-23 EP EP08842668A patent/EP2207669A4/en not_active Withdrawn
- 2008-10-27 JP JP2010531321A patent/JP5647897B2/ja not_active Expired - Fee Related
- 2008-10-27 CN CN200880122809.4A patent/CN101909649B/zh not_active Expired - Fee Related
- 2008-10-27 EP EP08841984.1A patent/EP2214712B1/en not_active Not-in-force
- 2008-10-27 AU AU2008316556A patent/AU2008316556B2/en not_active Ceased
- 2008-10-27 CA CA2703714A patent/CA2703714A1/en not_active Abandoned
- 2008-10-27 CN CN201310717654.1A patent/CN103721258B/zh not_active Expired - Fee Related
-
2010
- 2010-04-25 IL IL205321A patent/IL205321A0/en unknown
- 2010-04-25 IL IL205320A patent/IL205320A/en active IP Right Grant
-
2014
- 2014-11-10 JP JP2014228037A patent/JP5750540B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011500854A5 (https=) | ||
| JP2012506451A5 (https=) | ||
| JP2012525396A5 (https=) | ||
| HRP20200298T1 (hr) | Pripravci za respiratorno davanje aktivnih sredstava i pripadajući postupci i sustavi | |
| JP2014511879A5 (https=) | ||
| JP2011523627A5 (https=) | ||
| ES2659328T3 (es) | Uso de una composición de glucocorticoides para el tratamiento de asma grave e incontrolada | |
| HRP20201711T1 (hr) | Postupci liječenja autoimunih, respiratornih i upalnih poremećaja inhalacijom roflumilast n-oksida | |
| HRP20140864T1 (hr) | Kombinacije koje sadrže antimuskarinska sredstva i beta-adrenergiäśke agoniste | |
| Donnelly et al. | Clinical pharmacokinetics of inhaled budesonide | |
| ES2759247T3 (es) | Antagonistas muscarínicos y combinaciones de estos para el tratamiento de enfermedades de las vías respiratorias en caballos | |
| US20030186843A1 (en) | Powders for use in a dry powder inhaler | |
| Thorsson et al. | Factors guiding the choice of delivery device for inhaled corticosteroids in the long-term management of stable asthma and COPD: focus on budesonide | |
| CA2798127A1 (en) | Methods and compositions for protecting against neurotoxic agents | |
| EP2682098B1 (en) | Inhalation Compositions | |
| JP2007509941A5 (https=) | ||
| JP2018087203A (ja) | ４級アンモニウムムスカリン受容体アンタゴニストの噴霧可能組成物 | |
| KR101475262B1 (ko) | 천식 치료에 사용되는 흡입용 복합 조성물 | |
| JP2007505829A5 (https=) | ||
| Berger et al. | The use of inhaled corticosteroids for persistent asthma in infants and young children | |
| Nicolini et al. | Inhaled corticosteroid therapy with nebulized beclometasone dipropionate | |
| US10383883B2 (en) | Treatment of congestion using steroids and adrenergics | |
| CN112839633A (zh) | 包含药剂的低共熔溶剂及其制造方法和用途 | |
| Scichilone et al. | Revising old principles of inhaled treatment in new fixed combinations for asthma | |
| Gad | Safety assessment of therapeutic agents administered by the respiratory route |